Table 3

Overall survival of patients with stage I lung adenocarcinoma in relation to molecular and clinicopathological characteristics

VariableSubsetIncidencea (%)P
UnivariatebMultivariatec
GenderMale21/64 (33)0.01500.077
Female5/46 (11)(Risk ratio 2.440; 95% CI, 0.907–6.565)
Age<605/41 (12)0.06700.125 (<60 vs. 60–69)
60–6910/39 (26)(Risk ratio 2.375; 95% CI, 0.786–7.175)
>6911/30 (37)0.032 (<60 vs. ≥69)
(Risk ratio 3.190; 95% CI, 1.084–9.388)
Smoking historySmoker18/62 (29)0.1617NSd
Nonsmoker8/48 (17)
T stageT113/75 (17)0.06000.104
T213/35 (37)(Risk ratio 1.934; 95% CI, 0.873–4.292)
DifferentiationPoorly4/17 (24)0.9664NS
Moderately9/37 (24)
Well13/56 (23)
Vascular invasion+11/31 (35)0.1190NS
15/79 (19)
Lymphatic permeation+7/22 (32)0.1922NS
19/88 (22)
Pleural involvement+8/26 (31)0.4143NS
18/84 (21)
RASSF1A methylation+13/35 (37)0.03680.032
13/75 (17)(Risk ratio 2.357; 95% CI, 1.075–5.169)
p53 mutation+12/37 (32)0.1630NS
14/73 (19)
K-ras mutation+1/13 (8)0.1818NS
25/97 (26)
AI at 3p21.3+11/42 (26)0.7243NS
12/61 (20)
  • a Incidence is expressed by the number of patients who died of lung cancer per the number of patients in total.

  • b Log-rank test.

  • c Stepwise Cox proportional hazards regression model.

  • d NS, not selected in stepwise Cox proportional regression model.